India's Pharma Future Gets a $1.5B Boost from Roche

Swiss healthcare leader Roche Pharma has announced plans to invest a minimum of 1.5 billion Swiss francs (approx. ₹14,000 crore) in India over the next five years, reaffirming its long-term commitment to the country’s rapidly evolving healthcare landscape.

The announcement was made by Francois du Toit, Area Head for CEETRIS (Central Eastern Europe, Türkiye, Russia, and the Indian Subcontinent), during the India-European Free Trade Association (EFTA) Prosperity Summit. The declaration aligns with the recent implementation of the India-EFTA Free Trade Agreement, which is expected to bolster trade and investment flows between India and EFTA member states.

Roche, which currently employs over 5,000 professionals in India, plans to focus its investment on three key areas, including:

Research and Development (R&D), Partnerships with national healthcare initiatives, including Ayushman Bharat

Improving access to innovative medicines and healthcare solutions for a broader patient population

This strategic commitment reinforces India’s position as both a critical growth market and an emerging hub for healthcare innovation in the global pharmaceutical ecosystem.

News by Rahul Yelligetti.